ARS Pharmaceuticals Inc - SPRY Operating Profitability

SPRY (ARS Corp) - company brandmark

The emergency allergy relief market is expanding as patients shift toward needle-free sprays, where ARS Pharmaceuticals (SPRY) is setting the trend for convenience. The operating margin timeline demonstrates business efficiency, with the value of -161.50 serving as the current metric. The company's success is based on scaling Neffy sales, expanding insurance coverage, and increasing market share by displacing injectors.

SPRY: ars-pharma.com Operating Profit Rate 04/28/2023 - 11/19/2026

ars-pharma.com - analytical breakdowns and key metrics (SPRY)

- stock quotes and analyst forecast:
Comprehensive company analysis:ARS Pharmaceuticals Inc, SPRY
Core merchandise of ARS Pharmaceuticals

When assessing the asset quality of ARS Pharmaceuticals (SPRY), I focus on the efficiency of cost management. By analyzing the operating profit margin, an investor can see the portion of revenue remaining after paying operating expenses, before taxes and interest. This metric measures the intrinsic profitability of the business model. For ARS Pharmaceuticals, this indicator reflects the commercial potential of introducing the innovative Neffy spray into emergency medicine. Margin growth confirms the high capitalization of the company's intellectual property.

Main competitors

Operating Profitability haleon.com|Operating Profitability KVUE|Operating Profitability Verona Pharma (VRNA)|Jyong Biotech (MENS) - Operating Profitability Margin|Operating Margin LGND (Ligand Pharma)|Amneal Pharmaceuticals Inc - Operating Profitability|PRGO - Operating Profitability|Alvotech Corp (ALVO) - Operating Sales Margin|LQDA: Operating Margin|Operating Return on Sales glpg.com (GLPG)|Operating Profitability ANI Pharmaceuticals Inc|MNKD: Operating Profit Rate|Operating Sales Margin AMPH (Amphastar)|PCRX - Operating Return on Sales|Theravance Biopharma - Operating Sales Margin|Operating Profit Ratio AQST (Aquestive Therapeutics)|SCPH: Operating Sales Margin|Operating Return on Sales Tectonic Therapeutic|TNXP: Operating Margin|SXT China (SXTC) - Operating Margin|Operating Profitability eupraxiapharma.com|BioHarvest Sciences (BHST) - Profitability of Operations|Operating Profitability Invizyne (EXOZ)|ORMP - Operating Return on Sales|Operating Margin ENTX (Entera Bio)|Operating Profitability Margin MindWalk Therapeutics|ABVC: Operating Sales Margin|CPIX - Operating Margin|QNTM (Quantum BioPharma) - Operating Sales Margin|Operating Profit Margin FGEN (FibroGen)|TELO (Telomir Pharmaceuticals Corp) - Operating Margin|Operating Margin ranitherapeutics.com|Operating Profitability Synergy CHC Corp. (SNYR)|Rallybio Corp - Return on Sales by Operating Profit|lexariabioscience.com - Operating Sales Margin|Operating Margin Pulmatrix Inc PULM|Pheton Holdings - Operating Margin|Operating Profit Margin APM|Lyra Therapeutics, Inc. (LYRA) - Operating Profitability|Operating Return on Sales Impact BioMedical, Inc. (IBO)|Operating Profitability TNF Pharma|YCBD: Operating Profit Rate|Operating Margin PRFX|CYTO - Operating Return on Sales|Operating Profitability Lipella LIPO|Operating Profit Ratio OPTN (OptiNose, Inc.)|PIRS - Operating Profitability|Procaps (PROC) - Operating Sales Margin|PTPI: Operating Margin|Qilian International (QLI) - Operating Margin|Operating Profitability Acelyrin, Inc.|Operating Margin TFF Pharmaceuticals, Inc.